Live Oak Investment Partners Has $161,000 Holdings in Amgen Inc. (NASDAQ:AMGN)

Live Oak Investment Partners trimmed its stake in Amgen Inc. (NASDAQ:AMGN) by 19.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned 616 shares of the medical research company’s stock after selling 149 shares during the period. Live Oak Investment Partners’ holdings in Amgen were worth $161,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Swedbank AB increased its stake in Amgen by 1.1% during the third quarter. Swedbank AB now owns 538,899 shares of the medical research company’s stock valued at $173,639,000 after acquiring an additional 5,751 shares during the period. Greenwood Capital Associates LLC grew its holdings in shares of Amgen by 23.4% during the 3rd quarter. Greenwood Capital Associates LLC now owns 52,096 shares of the medical research company’s stock worth $16,786,000 after purchasing an additional 9,871 shares in the last quarter. W.H. Cornerstone Investments Inc. increased its position in shares of Amgen by 10.5% during the third quarter. W.H. Cornerstone Investments Inc. now owns 1,000 shares of the medical research company’s stock valued at $322,000 after purchasing an additional 95 shares during the period. Global Wealth Management Investment Advisory Inc. raised its stake in shares of Amgen by 0.8% in the third quarter. Global Wealth Management Investment Advisory Inc. now owns 5,429 shares of the medical research company’s stock valued at $1,749,000 after purchasing an additional 41 shares in the last quarter. Finally, NorthRock Partners LLC lifted its position in Amgen by 1.1% in the third quarter. NorthRock Partners LLC now owns 4,228 shares of the medical research company’s stock worth $1,362,000 after purchasing an additional 45 shares during the period. Institutional investors own 76.50% of the company’s stock.

Insiders Place Their Bets

In other Amgen news, EVP Murdo Gordon sold 8,771 shares of Amgen stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $294.79, for a total transaction of $2,585,603.09. Following the completion of the sale, the executive vice president now owns 44,186 shares of the company’s stock, valued at approximately $13,025,590.94. The trade was a 16.56 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Nancy A. Grygiel sold 1,589 shares of the firm’s stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the transaction, the senior vice president now owns 7,210 shares in the company, valued at $2,195,228.70. This represents a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 69,341 shares of company stock valued at $20,644,335. 0.69% of the stock is currently owned by insiders.

Amgen Trading Up 0.5 %

Shares of NASDAQ AMGN opened at $312.19 on Wednesday. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. The company has a 50-day moving average of $282.76 and a two-hundred day moving average of $299.66. The company has a market cap of $167.71 billion, a PE ratio of 41.35, a P/E/G ratio of 2.63 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. As a group, equities analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be given a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.05%. Amgen’s payout ratio is 126.09%.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Leerink Partners lowered their price target on shares of Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Truist Financial lowered their target price on shares of Amgen from $333.00 to $298.00 and set a “hold” rating on the stock in a research note on Wednesday, January 8th. Jefferies Financial Group restated a “buy” rating and set a $380.00 price target on shares of Amgen in a research note on Tuesday, November 12th. Wolfe Research assumed coverage on Amgen in a research note on Friday, November 15th. They issued a “peer perform” rating on the stock. Finally, Piper Sandler raised their target price on Amgen from $310.00 to $329.00 and gave the stock an “overweight” rating in a research report on Monday, February 10th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Amgen presently has an average rating of “Hold” and a consensus price target of $314.09.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.